Oragenics (OGEN) Non-Current Assets (2010 - 2024)
Oragenics' (OGEN) quarterly Non-Current Assets came in at $1.1 million in Q3 2024, up 1178.18% YoY from $85336.0 in Q4 2023, and little changed on a QoQ basis from $1.1 million in Q2 2024.
Oragenics (OGEN) Non-Current Assets (2010 - 2024) Analysis & Trends
Oragenics (OGEN) has 15 years of Non-Current Assets data on file, last reported at $1.1 million in Q3 2024.
- Quarterly Non-Current Assets rose 1178.18% year-over-year to $1.1 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $1.1 million (down 67.61% YoY) and the FY2023 annual result came in at $1.1 million, up 134.91% from the prior year.
- Non-Current Assets was little changed at $1.1 million in Q3 2024, from $1.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.1 million in Q4 2023 to a low of $85336.0 in Q3 2023.
- A 5-year average of $669604.1 and a median of $585851.0 in 2021 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets sank 83.83% — and 2024, when it soared 1178.18%.
- Tracing OGEN's Non-Current Assets over 5 years: stood at $697851.0 in 2020, then slipped by 24.97% to $523590.0 in 2021, then decreased by 10.52% to $468502.0 in 2022, then surged by 134.91% to $1.1 million in 2023, then retreated by 0.89% to $1.1 million in 2024.
- The last three Non-Current Assets figures came in at $1.1 million (Q3 2024), $1.1 million (Q2 2024), and $1.1 million (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 1.10 Mn |
| Sep 30, 2023 | 85,336.00 |
| Jun 30, 2023 | 365,652.00 |
| Mar 31, 2023 | 426,423.00 |
| Dec 31, 2022 | 468,502.00 |
| Sep 30, 2022 | 527,817.00 |
| Jun 30, 2022 | 495,141.00 |
| Mar 31, 2022 | 553,806.00 |
| Dec 31, 2021 | 523,590.00 |
| Sep 30, 2021 | 555,847.00 |
| Jun 30, 2021 | 585,851.00 |
| Mar 31, 2021 | 642,160.00 |
| Dec 31, 2020 | 697,851.00 |
| Sep 30, 2020 | 752,936.00 |
| Jun 30, 2020 | 807,427.00 |
| Mar 31, 2020 | 861,328.00 |
| Dec 31, 2019 | 914,652.00 |